 
Gas for VMT v3.0 7 -24-19           
     
DRCR Retina Network  
 
 
 
 
Randomized Clinical Trial Assessing the 
Effects of Pneumatic Vitreolysis on 
Vitreomacular Traction   
(Protocol A G) 
 
 
IDE Sponsor : Jaeb Center for Health Research  (JCHR)  
 
Version 3.0 
 
24 July 2019  
 
NCT0364726 7 
 
 
Gas for VMT v3.0 7 -24-19           
    Signature [CONTACT_759076]: DRCR Retina Network  AG 
IDE Sponsor: Jaeb Center for Health Research  
Version Number: 3.0 
24 July 2019  
 
 
 
JCHR Principal Investigator   
[CONTACT_5627], degree  Adam Glassman, MS  
 
Signature / Date   
 
 
 
 
 
 
 
Jaeb Center for Health Research  
Gas for VMT v3.0 7 -24-19           
    KEY ROLES  
 
Protocol Chair   
Name, degree  Clement K. Chan, MD, FACS  
Title  Medical Director  
Institution Name  [CONTACT_759077], Palm Desert, CA  
 
JCHR Coordinating Center Director   
Name, degree  Adam Glassman, MS  
Title  Director  of DRCR Retina Network  Coordinating Center  
Institution Name  [CONTACT_352741] , Tampa, FL  
 
Network Chair   
Name, degree  Daniel F. Martin, MD  
Title  Chairman, Cole Eye Institute  
Institution Name  [CONTACT_491207], Cleveland Clinic, Cleveland, Ohio  
 
Medical Monitor   
Name, Title  Robert Lindblad, Senior Medical Officer  
Ashraf El Fiky, Medical Officer  
Institution Name  [CONTACT_759078] v3.0 7 -24-19           
    TABLE OF CONTENTS  
Chapter 1:  Background Information and Study Synopsis  ................................ ..........................  1-1 
1.1. Introduction  ................................ ................................ ................................ ...................  1-1 
1.1.1 Vitreoretinal Interface Abnormalities  ................................ ................................ .........  1-1 
1.1.2 Treatments for VMT  ................................ ................................ ................................ ... 1-1 
1.1.3 Pneumatic Vitreolysis (PVL)  ................................ ................................ ......................  1-2 
1.2. Rationale  ................................ ................................ ................................ ........................  1-2 
1.3 Study Objectives  ................................ ................................ ................................ ...........  1-2 
1.4 Potential Risks and Benefits of C 3F8 Gas Injection  ................................ .......................  1-3 
1.4.1 Known Potential Risks  ................................ ................................ ................................  1-3 
1.4.2 Known Potential Benefits  ................................ ................................ ...........................  1-4 
1.4.3 Risk Assessment  ................................ ................................ ................................ .........  1-4 
1.5 General Considerations  ................................ ................................ ................................ . 1-4 
Chapter 2:  Study Participant Eligibility and Enrollment  ................................ ...........................  2-1 
2.1 Randomized Trial Participant Recruitment and Enrollment  ................................ ..............  2-1 
2.2 Participant Eligibility Criteria  ................................ ................................ ............................  2-1 
2.2.1 Participant -level Criteria  ................................ ................................ .............................  2-1 
2.2.2 Study Eye Criteria  ................................ ................................ ................................ ....... 2-2 
2.3 Screening Evaluation and Baseline Testing  ................................ ................................ ....... 2-4 
2.3.1 Baseline Testing Procedures  ................................ ................................ .......................  2-4 
2.4 Randomization of Eligible Participants  ................................ ................................ .............  2-5 
Chapter 3:  Baseline Treatment  ................................ ................................ ................................ ... 3-[ADDRESS_1039218] -Injection  ................................ ................................ ...............  3-1 
Chapter 4:  Follow -Up Visits and Testing  ................................ ................................ ..................  4-1 
4.1 Study Visits  ................................ ................................ ................................ ........................  4-1 
4.1.1 Procedures at Study Visits  ................................ ................................ ..........................  4-1 
4.1.2 Unscheduled Visits  ................................ ................................ ................................ ..... 4-1 
4.2 Treatment During Follow -Up ................................ ................................ ............................  4-2 
4.2.1 Criteria for Vitrectomy  ................................ ................................ ...............................  4-2 
Jaeb Center for Health Research  
Gas for VMT v3.0 7 -24-19           
    4.2.2 Treatment for Other Conditions in the Study Eye  ................................ ......................  4-2 
4.2.3 Treatment in the Non -Study Eye  ................................ ................................ ................  4-2 
Chapter 5:  Study Device  ................................ ................................ ................................ ............  5-1 
5.2 Study Device Accountability Procedures  ................................ ................................ ..........  5-1 
5.3 Safety Measures  ................................ ................................ ................................ .................  5-1 
Chapter 6:  Adverse Events, Device Issues, and Stoppi[INVESTIGATOR_1869]  ................................ ...............  6-1 
6.1 Adverse Events  ................................ ................................ ................................ ..................  6-1 
6.1.1 Definitions ................................ ................................ ................................ ...................  6-1 
6.1.2 Reportab le Adverse Events  ................................ ................................ .........................  6-2 
6.1.3 Relationship of Adverse Event to Study Device ................................ .........................  6-2 
6.1.4 Intensity of Adverse Event ................................ ................................ ..........................  6-2 
6.1.5 Coding of Adverse Events  ................................ ................................ ..........................  6-3 
6.1.6 Outcome of Adverse Event  ................................ ................................ .........................  6-3 
6.2 Reportable Device Issues  ................................ ................................ ................................ ... 6-4 
6.3 Pregnancy Reporting  ................................ ................................ ................................ ..........  6-4 
6.4 Timing of Event Reporting  ................................ ................................ ................................  6-4 
6.5 Stoppi[INVESTIGATOR_2121]  ................................ ................................ ................................ ................  6-4 
6.5.1 Criteria for Suspending or Stoppi[INVESTIGATOR_3396]  ................................ ....................  6-4 
6.6 Independent Safety Oversight  ................................ ................................ ............................  6-5 
6.7 Risks  ................................ ................................ ................................ ................................ ... 6-5 
Chapter 7:  Miscellaneous Considerations  ................................ ................................ ..................  7-1 
7.1 Prohibited Medications, Treatments, and Procedures  ................................ ........................  7-1 
7.2 Participant Withdrawal  ................................ ................................ ................................ ...... 7-1 
7.3 Discontinuation of Study  ................................ ................................ ................................ ... 7-1 
7.4 Confidentiality  ................................ ................................ ................................ ...................  7-1 
7.5 Particip ant Compensation  ................................ ................................ ................................ .. 7-1 
Chapter 8:  Statistical Considerations  ................................ ................................ .........................  8-1 
8.1 Statistical and Analytical Plans  ................................ ................................ ..........................  8-1 
8.2 Statistical Hypotheses  ................................ ................................ ................................ ........  8-1 
8.3 Sample Size  ................................ ................................ ................................ ........................  8-1 
8.3.1 Outcome Projections:  ................................ ................................ ................................ .. 8-1 
8.3.2 Sample Size Estimates  ................................ ................................ ................................  8-1 
8.4 Outcome Measures ................................ ................................ ................................ .............  8-2 
8.5 Analysis Cohorts  ................................ ................................ ................................ ................  8-3 
Jaeb Center for Health Research  
Gas for VMT v3.0 7 -24-19           
    8.6 Analysis  of the Primary Efficacy Outcome  ................................ ................................ ....... 8-3 
8.7 Analysis of the Secondary and Exploratory Efficacy Outcomes  ................................ ....... 8-4 
8.8 Safety Analyses  ................................ ................................ ................................ ..................  8-5 
8.8.1 Ocular Adverse Events  ................................ ................................ ...............................  8-5 
8.8.2 Systemic Adverse Events  ................................ ................................ ............................  8-6 
8.9 Intervention Adherence  ................................ ................................ ................................ ...... 8-6 
8.10 Protocol Adherence and Retention  ................................ ................................ ..................  8-6 
8.11 Baseline Descriptive Statistics  ................................ ................................ .........................  8-6 
8.12 Planned Interim Analyses  ................................ ................................ ................................  8-6 
8.13 Subgroup Analyses  ................................ ................................ ................................ ..........  8-6 
8.14 Multiple Testing  ................................ ................................ ................................ ...............  8-7 
8.15 Assessment of Confounding  ................................ ................................ ............................  8-7 
Chapter 9:  Data Collection and Monitoring  ................................ ................................ ...............  9-1 
9.1 Case Report Forms and Device Data  ................................ ................................ .................  9-1 
9.2 Study Records Retention ................................ ................................ ................................ .... 9-1 
9.3 Quality Assurance and Moni toring  ................................ ................................ ....................  9-1 
9.4 Protocol Deviations  ................................ ................................ ................................ ............  9-2 
Chapter 10:  Ethics/Protection of Human Participants  ................................ .............................  10-[ADDRESS_1039219]  ................................ ................................ ................................ .............  10-1 
10.2 Institutional Review Boards  ................................ ................................ ...........................  10-1 
10.3 Informed Consent Process  ................................ ................................ .............................  10-1 
10.3.1 Consent Procedures and Documentation  ................................ ................................  10-1 
10.3.2 Participant and Data Confidentiality  ................................ ................................ ....... 10-1 
10.3.3 Future Use of Stored Specimens  ................................ ................................ .............  10-2 
Chapter 11:  References  ................................ ................................ ................................ ............  11-[ADDRESS_1039220]  
VMT  Vitreomacular Traction  
VMA  Vitreomacular Adhesion  
 
JAEB CENTER FOR HEALTH RESEARCH  
Gas for VMT v3.0 7 -24-19           
    PROTOCOL SUMMARY  
PARTICIPANT AREA  DESCRIPTION  
Title  Randomized Clinical Trial Assessing the Effects of 
Pneumatic Vitreolysis on Vitreomacular Traction  
Précis  Eyes with idiopathic symptomatic vitreomacular traction 
(VMT) without a macular hole will be randomly assigned to 
0.3-mL intraocular gas  (C3F8) injection or sham injection to 
determine if pneumatic vitreolysis (PVL) is effective in 
releasing VMT . 
Investigational Device  0.3-mL intraocular gas (C 3F8) injection  
Objectives  Primary  
1. To compare the proportion of eyes with central  
VMT  release on OCT after pneumatic vitreolysis 
with gas injection versus observation (sham  
injection ) in eyes with VMT  without an associated 
macular hole .  
Secondary  
2. To evaluate visual function outcomes at 24 weeks 
after gas injection is performed compared with sham 
injection .  
Study Design  Multi -center , randomized  clinical trial  
Number of Sites  Approximately 50 sites  
Endpoint  Primary Outcome:  Proportion  of eyes with central  VMT 
release  on optical coherence tomography ( OCT ) without 
rescue treatment  at 24 weeks . 
 
Key Secondary Outcomes: Proportion of eyes with rescue 
treatment, mean change in visual acuity  
 
Key Safety Outcomes: Retinal tear, retinal detachment, 
macular hole development,  traumatic cataract,  cataract  
extraction , vitreous  hemorrhage, intraocular press ure (IOP)  
increase,  and endophthalmitis . 
Population  Key Inclusion Criteria  
• Age ≥18 years.  
• Able and willing to avoid high altitude travel until 
gas resolution (approximately 6 to 8 weeks ).  
• For phakic patients, a ble and willing to avoid supi[INVESTIGATOR_759054]  (approximately 6 to 
8 weeks) . 
• At least one eye with  each of the following : 
JAEB CENTER FOR HEALTH RESEARCH  
Gas for VMT v3.[ADDRESS_1039221] that is 
no larger than 3000 microns , confirmed by 
[CONTACT_491195] , 
o decreased visual function (e.g. metamorphopsia 
or other visual symptom) that is attributed to 
VMT ,  
o best corrected Early Treatment Diabetic 
Retinopathy Study ( ETDRS ) visual acuity 
equivalent of 20/ 32 to 20/400 , and  
o prompt vitrectomy not required  
Key Exclusion Criteria  
• Macular or lamellar hole . 
• Other condition that might affect visual acuity 
during the course of the study (e.g. retinal vein 
occlusion , advanced age-related macular 
degeneration , or macular edema induced by a 
condition other than VMT) . 
o Note: Epi[INVESTIGATOR_759055] a requirement.  
• High level myopia ( -8.00 diopters or more  negative 
if phakic; retinal abnormalities consistent with 
pathologic myopia if phakic or pseudophakic ). 
• Prior gas injection, ocriplasmin injection, or 
intraocular injection for any  reason . 
• Prior vitrectomy . 
Sample Size  Minimum of 124 eyes 
Treatment Groups  Random assignment (1:1) to one of the following:  
Group A: PVL ( 0.3-mL C 3F8 injection ) 
Group B: Observation  (Sham injection ) 
Participant Duration  24 weeks  
Protocol 
Overview/Synopsis  1. Informed consent will be obtained for screening.  
2. Eligibility will be assessed, including reading center 
confirmation of VMT  on OCT .  
3. Eligible eyes will be randomly assigned to C 3F8 
injection (0.3  mL) or sham  injection , which will be 
performed on the day of randomization .  
4. Follow -up will occur a t 1, 4, [ADDRESS_1039222] of vision testing (including visual acuity  and 
visual function ( myVisionTrack ), ocular exam, and 
OCT .  
5. Rescue vitrectomy may be performed if there is a 10 
or more letter  decrease at one visit or 5 or more 
letter decrease at two consecutive  visits compared 
JAEB CENTER FOR HEALTH RESEARCH  
Gas for VMT v3.0 7 -24-19           
    PARTICIPANT AREA  DESCRIPTION  
with baseline that is thought to be associated with 
VMT, or a complication that requires prompt 
surgical intervention (e.g. macular hole , retinal 
detachment, non -clearing vitreous hemorrhage ). 
Otherwise, alternative treatment may not be 
performed without discussion with and approval 
from the protocol chair or designee .  
6. The primary outcome assessment will be the 
proportion  of eyes with  central  VMT r elease  on 
OCT at 24 weeks  without rescue treatment . 
JAEB CENTER FOR HEALTH RESEARCH  
Gas for VMT v3.0 7 -24-19           
    SCHEMATIC OF STUDY DESIGN  
 Dropped IneligibleInformed Consent Obtained
Baseline Testing
Randomization
Injection of C3F8
Gas (0.3 mL)
1 week
4 week
12 week
24 week
Primary OutcomeObservation 
(Sham injection)
1 week
4 week
12 week
24 week
Primary OutcomeReading Center Review
Dropped 
Ineligible
Follow -Up Treatment  
Vitrectomy permitted in both arms if 
one of the following:  
1) Visual acuity  decreases ≥10 
letters  at one visit or ≥5 
letters at two consecutive 
visits  
2) Complication requires 
prompt surgical 
intervention (e.g. , macular 
hole)  Follow -Up Treatment  
Vitrectomy permitted in both arms if 
one of the following:  
1) Visual acuity  decreases ≥10 
letters  at one visit or ≥5 
letters at 2 consecutive 
visits (not including the 1 -
week visit) compared with 
baseline that is thought to 
be related to VMT.  
2) Complication requires 
prompt surgical 
intervention (e.g. , macular 
hole, retinal detachment, 
non-clearing vitreous 
hemorrhage ). 
 
JAEB CENTER FOR HEALTH RESEARCH  
Gas for VMT v3.0 7 -24-19           
    SCHEDULE OF STUDY VISITS AND PROCEDURES  
 
 Baseline Testing 
and 
Randomization*  [ADDRESS_1039223] corrected visual acuity a X X X 
Visual function testing  
(myVisionTrack) b X  X 
OCT c X X X 
Eye exam d X X X 
Reading center eligibility confirmation e X   
Randomized treatment (gas or sham 
injection) X   
* All baseline testing must occur within 8 days prior to randomization . Baseline testing  and randomization can occur 
on the same day if eligibility is confirmed by [CONTACT_759064] .  
 
a, Both eyes at all visits; includes protocol refraction in study eye only at 1, 4, and 12 weeks and in both eyes at baseline and 24 
week s; E-ETDRS refers to electronic ETDRS testing using the Electronic Visual Acuity Tester that has been validated against 4 -
meter chart ETDRS testing.  
b, At baseline , 12, and 24 weeks . 
c, Both eyes at baseline; study eye only at follow up visits.  
d, Both eyes at  baseline; study eye only at each follow -up visit . Includes slit lamp exam (including assessment of lens), 
measurement of IOP, and dilated ophthalmoscopy.  Scleral depression is required at baseline to confirm eligibility. During follow 
up, the eye exam should be extensive enough to identify adverse event s of interest . An extended ophthalmoscopy including a  
scleral depression is required at 1, 4, and [ADDRESS_1039224] occur prior to randomization .
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         1-1  
   CHAPTER 1:  BACKGROUND INFORMATION AND STUDY SYNOPSIS  1 
 2 
1.1. Introduction  3 
1.1.1 Vitreoretinal Interface Abnormalities  4 
Disorders of the vitreoretinal interface represent a spectrum of abnormalities that develop as the 5 
posterior hyaloid separates from the internal limiting membrane . Vitreomacular adhesion (VMA) 6 
occurs when the posterior hyaloid remains attached to the internal limiting membrane centrally . 7 
Overall, about 1.5% of the population is estimated to have eye diseases caused by [CONTACT_491191] 8 
with VMA.1 The incidence of VMA diagnoses is expected to increase with widespread use of 9 
spectral -domain optical coherence tomography ( OCT ). Vitreomacular traction (VMT) is [ADDRESS_1039225] , are likely an underestimation . Advanced VMT 14 
can lead to macular holes (MH), in which tractional forces create small , full-thickness defects on [ADDRESS_1039226] 19 
been multiple reports in the literature of spontaneous resolution of VMT. 3-8 Based on a 20 
Cochrane Eyes and Vision systematic review of 4 trials with 932 eyes, the 28 -day VMA release 21 
rate among eyes in the control groups (sham or saline injection) is estimated to be 97  of 1000 22 
eyes.9 In the Intravitreal Inj ection -Traction Release Without Surgical T reatment (MIVI -TRUST) 23 
trials,10 10% of the placebo -vehicle injected eyes developed a spontaneous posterior vitreous 24 
detachment ( PVD ) by 28 days, increasing to about 13% through 180 days . The Ocriplasmin for 25 
Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Trial 26 
reported success of VMT release of 6% in the sham group at 28 days, increasing to 14% over 2 27 
years.11 In a 2014  retrospective case series , John et al6 reported spontaneous PVD in 32% of eyes 28 
with focal VMA (document ed by [CONTACT_211682] -domain OCT) and good vision ( mean  visual acuity: 29 
20/37) with a median follow -up time of [ADDRESS_1039227] trial showed that ocriplasmin  (Jetrea®), a proteolytic enzyme for 37 
treatment of symptomatic VMA , induced a PVD in 26.5% of eyes versus 10.1% of placebo - 38 
vehicle injected eyes.10, 12 The success was shown to increase to 40% in eyes without epi[CONTACT_190773] 39 
membrane.10 In 2016, Lim et al reported in the Macula Society Collaborative Retrospective 40 
Study a rate of 45% in release of VMT after ocriplasmin.[ADDRESS_1039228] created major concerns 47 
among many retinal surgeons in the clinical use o f this drug.14-18 In a recent American Socie ty of 48 
Retina Specialists Preferences and Trends Survey, only 7% of retina specialists recommended [ADDRESS_1039229] line therapy for VMT and visual acuity of 20/60  or worse .19 50 
1.1.3 Pneumatic Vitreolysis  (PVL)  51 
Pneumatic vitreolysis (intraocular injection of expansile gas to induce a PVD) has b een [ADDRESS_1039230] demonstrated and reported the utility of intraocular gas (C 3F8) injection in 54 
eliciting a PVD (9 5%) in 1995.20 Subsequently, Costa et al, and Jorge et al showed a high rate of 55 
success in the induction of PVD (100%) with C 3F8 in small case series.21, 22 Recently, Rodrigues 56 
et al, in a series of fifteen eyes, showed resolution of VMT in 40% at one month and 60%  by 6 57 
months after injection of C 3F8 gas.23 Steinle et al reported a success rate of 83% with C 3F8 gas in 58 
a retrospective case series for treatment of VMT syndrome.24 In a 2016  retrospective review of 59 
50 consecutive eyes receiving C 3F8 gas for PVL  performed in 2 centers , Chan and Mein reported  60 
a success rate of 86% in VMT release (80% success for VMT -only eyes and 100% for small 61 
stage  2 MH [≤ 250 microns]).25 In 2019, Chan and Mein provided an update on this study and 62 
reported a success rate of 85% among 80 e yes (80.7% in eyes with VMT -only, 95.7% in eyes 63 
with macular hole) .[ADDRESS_1039231] from  PVL  with gas 83 
injection versus observation (sham  injection ) in eyes with VMT  without an associated 84 
MH.  85 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         1-3  
   Secondary  86 
2. To evaluate visual function outcomes at 24 weeks after gas injection is performed 87 
compared with observation.  88 
1.4 Potential Risks and Benefits of C3F8 Gas Injection  89 
1.4.1 Known Potential Risks  90 
• Pain, discomfort, redness, or itching lasting for a few days is likely.  91 
• Subconjunctival hemorrhage or floaters will commonly occur as a result of the injection . The [ADDRESS_1039232].  93 
• Immediately following the injection, there may be elevation of IOP. It usually returns to 94 
normal spontaneously, but may need to be treated with topi[INVESTIGATOR_759056] a paracentesis to 95 
lower the pressure . The likelihood of permanent loss of vision from elevated IOP is less than 96 
1%. 97 
• Although it has not been reported in prior case series, endophthalmitis could theoretically 98 
develop . The risk of endophthalmitis from other intraocular injections is less than 1%.  99 
• A retinal tear or detachment could occur . The risk of retinal breaks and/or detachment after 100 
gas injection is approximately  5-13%. The risk of retinal detachment is increased if there are 101 
pre-existing periphera l retinal abnormalities such as lattice degeneration or cystic tufts.  102 
• There is a possibility of traumatic cataract from the injection. The risk of developi[INVESTIGATOR_007] a [ADDRESS_1039233] from the injection is <1%.   104 
• If paracentesis is performed, there is a similar risk  of traumatic cataract from the 105 
paracentesis.  106 
• If vitrectomy is required while gas is in the eye, there is high likelihood of cataract formation [ADDRESS_1039234] removal at the time of vitrectomy.  108 
• Progression to MH after gas injection is a potential complication. Previous retrospective [ADDRESS_1039235] shown this complication to be <5%  110 
• Limited and transient uveitis may develop after gas injection . Persistent uveitis is uncommon.  111 
• Limited transient conjunctival or epi[INVESTIGATOR_759057] 112 
injection.  It is usually inconsequential and clears spontaneously from a few days to a week or 113 
two.  114 
• Limited vitreous hemorrhage after gas injection is uncommon but may occur occasionally 115 
after gas injection, particularly given a history of active anticoagulation therapy or 116 
predisposing risk for hemorrhage . If present, it usually resolves from a few days to a few 117 
months . Marked hemorrhage requiring a surgical intervention after gas injection is 118 
exceedingly rare  (<1%).  119 
• Pre-existing epi[INVESTIGATOR_491180] 120 
develop after gas injection.  121 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         1-4  
   • The development of excessive scarring on top of or under the retina after gas injection is [ADDRESS_1039236] -injection instructions:  125 
• IOP may increase if the patient experiences changes in elevation (i.e. trave l by [CONTACT_759065] 126 
mountain ranges)  while the gas bubble is still present in the eye . 127 
• Loss of vision or blindness  is possible  if nitrous oxide anesthesia is administered with the gas 128 
bubble still present in the eye . 129 
• Incorrect head positioning following the g as injection may lead to glaucoma or cataracts . [ADDRESS_1039237] their origin in the Declaration of Helsinki, with 140 
the protocol described herein, and with the standards of Good Clinical Practice (GCP).  [ADDRESS_1039238] recruitment at a particular site on hold as needed.  151 
All consented participants will be logged.  152 
The protocol is considered a significant risk device study because intraocular injection of C 3F8 is 153 
experimental for this indication . Therefore, an investigational device exemption (IDE) from the 154 
U.S. Food and Drug Administration (FDA) is required to conduct the study. 155 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         2-1  
   CHAPTER 2:  STUDY PARTICIPANT ELIGIBILITY AND ENROLLMENT  [ADDRESS_1039239] the overall 165 
recruitment goal.  166 
Potential eligibility may be assessed as part of a routine -care examination . Before completing 167 
any procedures or collecting any data that are not part of usual care, wr itten informed consent 168 
will be obtained.  169 
The study protocol will be discussed with the potential study participant by [CONTACT_464] . The 170 
potential study participant will be given the Informed Consent Form to read . Potential study 171 
participants will be encoura ged to discuss the study with family members and their personal 172 
physicians(s) before deciding whether to participate in the study.  [ADDRESS_1039240] not proceed to randomize an 180 
individual until he/she is convinced that the individ ual is eligible and will accept assignment to [ADDRESS_1039241] be met:  186 
1. Age ≥18 years .  187 
• Participants <[ADDRESS_1039242] one eye meets the study eye criteria listed in section 2.2.2.  190 
3. Able and willing to provide informed consent.  191 
4. Able and willing to avoid high altitude travel , including airline travel , until gas resolution 192 
(approximately 6 to 8 weeks ).  193 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         2-2  
   5. For phakic patients, a ble and willing to avoid supi[INVESTIGATOR_491181]  194 
(approximately 6 to 8 weeks ). [ADDRESS_1039243] band that informs any medical personnel that the patient has a 196 
gas bubble in the eye  197 
Exclusion  198 
A potential participant is not eligible if any of the following exclusion criteria are present:  199 
7. A condition that, in the opi[INVESTIGATOR_3078] n of the investigator, would preclude participation in the study 200 
(e.g., unstable medical status  that might preclude completion of follow -up) 201 
8. Participation in an investigational trial within 30 days of randomization that involves 202 
treatment with any drug or device that has not received regulatory approval for the indication 203 
being studied at the time of study entry  204 
• Note: study participants should not  receive another investigational drug /device  while 205 
participating in the study  206 
9. Known contraindication  to any component of the treatment  207 
10. Known allergy to any drug used in the procedure  prep (including povidone iodine)  208 
11. Potential participant is expecting to move out of the area of the clinical center to an area not 209 
covered by [CONTACT_759066] 6 months  following randomization  210 
12. Anticipated surgery requiring anesthesia within the next 6 months following randomization  211 
• Participants cannot receive nitrous oxide until gas resolution  212 
13. For women of child -bearing potential , pregnant at the time of enrollment  213 
• Women who are potential study participants should be questioned about the potential for [ADDRESS_1039244] only one study eye . If both eyes are eligible at the time of randomization, 220 
the study eye will be selected by [CONTACT_377430] .  221 
The eligibility criteria for a study eye are as follows:  [ADDRESS_1039245] that is no larger than 3000 microns  with visible 224 
separation of the vitreous on either side a s seen on horizontal and vertical scans , confirmed 225 
by [CONTACT_491195]  226 
Note: p resence of epi[INVESTIGATOR_759058] a requirement nor exclusion.  227 
b. Decreased visual function (e.g. metamorphopsia or other visual symptom) that is attributed to 228 
VMT.   229 
Examples of  visual  symptoms include:  230 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         2-3  
   a) Distortion and/or reduction in visual acuity  231 
b) Recognized difficulty with reading, driving, or using a computer  232 
c) Patient recognized interference with quality of life because of a and/or b.  [ADDRESS_1039246] 19 (appr oximate Snellen equivalent 20/400  or better ) and [ADDRESS_1039247] 78 (20/32 or worse)  236 
d. Investigator and participant willing to wait 6 months before surgical intervention , provided  237 
visual acuity remains stable   238 
• An eye that requires  prompt treatment for VMT should not be enrolled  [ADDRESS_1039248] visual acuity during the course of the study  or 241 
require intraocular treatment  (e.g., retinal vein occlusion , substantial age-related macular 242 
degeneration , or macular edema induced by a condition other than VMT)  243 
• If diabetic retinopathy is present, severity level must be microaneurysms only or better (≤  244 
diabetic retinopathy  severity level 20)  245 
• Presence of drusen is acceptable; however, eyes with geograph ic atrophy  or neovascular 246 
age-related macular degeneration involving the macula are excluded  247 
f. High level of myopia ( spherical equivalent of -8.00 diopters or more  myopic if phakic or 248 
retinal abnormalities consistent with pathologic myopia if phakic or pseudo phakic ) 249 
g. History of prior gas injection, ocriplasmin injection, or intraocular injection for any reason  250 
h. History of prior vitrectomy  251 
i. History of uncontrolled glaucoma  252 
• IOP must be <30  mmHg , with no more than one topi[INVESTIGATOR_759059], and no 253 
documented g laucomatous field loss for the eye to be eligible  254 
j. History of major ocular surgery (including cataract extraction, scleral buckle, any intraocular 255 
surgery, etc.) within prior 4 months or major ocular surgery anticipated within the next 6 256 
months following ra ndomization  257 
k. History of YAG capsulotomy performed within 4 months prior to randomization  258 
l. Aphakia  or anterior c hamber intraocular lens  259 
m. Exam evidence of severe external ocular infection, including conjunctivitis, chalazion, or 260 
substantial blepharitis  261 
n. Uveitis  262 
o. Presence of any macular hole or lamellar hole (according to reading center grading)  263 
p. Retinal history or pathology that might predispose an eye to an increased risk of retinal 264 
detachment from the procedure  265 
• Untreated retinal tears , not re tinal holes, are an exclusion.  It is up to the investigator to 266 
determine whether extent of lattice degeneration or other pathology might increase the 267 
risk of retinal detachment.  268 
q. Any contraindication to paracentesis (e.g ., history of narrow angle glaucoma)  [ADDRESS_1039249] be completed prior to 278 
randomization .  279 
2.3.1 Baseline Testing  Procedures  280 
The following procedures are needed to confirm eligibility and/or to serve as baseline measures 281 
for the study:   282 
• If a procedure has been performed using the study technique and by [CONTACT_377431] 283 
personnel as part of usual care, then it does not need to be repeated specifically for the 284 
study if it was performed within the defined tim e windows specified below.  285 
• The testing procedures are detailed in the DRCR Retina Network  Procedures Manuals . [ADDRESS_1039250] will be performed by 287 
DRCR Retina Network  certified personnel.  288 
1. Self-reported d emographics (date of birth, sex, race and ethnicity)  289 
2. Medical history (pre -existing medical conditions, concomitant medications, as well as ocular 290 
diseases, surgeries, and treatments ) 291 
➢ Medical history will be obtained by [CONTACT_759067]; 292 
otherwise, it will be self -reported  293 
3. Electronic -ETDRS visual acuity testing at 3 meters using the Electronic Visual Acuity Tester 294 
(including protocol refraction) in each eye  (within prior 8 days)  295 
4. Visual function testing ( myVisio nTrack ) (within prior 8 days)  296 
➢ Visual function testing will be performed using the myVisionTrack application on an 297 
iPad or tablet. myVisionTrack ® is an FDA cleared application to track disease [ADDRESS_1039251] that is shaped differently among a series of  side-by-side circles on the 300 
screen . The series  continues  with increasing difficulty  until the patient’s visual 301 
function is determined. Visual function is measu red using the shape discrimination 302 
hyperacuity (SDH) (logMAR) score.   [ADDRESS_1039252] using Zeiss Cirrus or Heidelberg Spectralis on each eye  (within prior 304 
8 days)  305 
➢ OCT  scans of the study eye will be promptly sent to the central reading center for 306 
gradi ng and a participant cannot be randomized until reading center confirmation of 307 
eligibility has been received  308 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         2-5  
   6. Ocular examination on each eye including slit lamp, measurement of IOP, lens assessment, 309 
and dilated ophthalmoscopy (within prior 8 days ) 310 
➢ Scleral depression to rule out any retinal tears pre -operatively will be required for the 311 
baseline eye exam to confirm eligibility  312 
2.4 Randomization of Eligible Participants  313 
Randomization may occur on the same day as baseline testing if eligibility is confirme d by [CONTACT_941] 314 
reading center on the day of screening .  315 
1. Prior to randomization, the participant’s understanding of the trial, willingness to accept the 316 
assigned treatment group, and commitment to the follow -up schedule should be reconfirmed.  317 
2. The baseline injection (or sham) must be given on the day of randomization; therefore, a 318 
participant should not be randomized until this is possible .  319 
3. Randomization is completed on the DRCR Retina Network  website .  320 
• Study eyes will be randomly assigned with equal probab ility to one of two treatment 321 
groups:  322 
o Group A: PVL ( Intravitreous injection of  0.3 mL  C3F8 gas) 323 
o Group B: Observation ( Sham injection ) 324 
Randomization will be stratified by [CONTACT_759068][INVESTIGATOR_43691] (ERM) [ADDRESS_1039253] not proceed to randomize an 330 
individual until he/she is convinced that the individual is eligible and will accept whichever 331 
treatment group is assigned through randomizati on. 332 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         3-1  
   CHAPTER 3:  BASELINE TREATMENT  333 
3.1 Treatment  334 
For both groups, the baseline injection (sham or intravitreous) must be given on the day of 335 
randomization .  336 
3.2 Injection  Procedure  337 
3.2.1 Intravitreous Injection Technique  338 
The injection is preceded by a povid one iodine prep of the conjunctiva . A subconjunctival 339 
injection of lidocaine may be administered , at the discretion of the investigator . The injection 340 
will be performed using sterile technique . Pre-injection paracentesis should be considered due to 341 
the 4x expansion of C 3F8 gas and the associated risk of shallowing of the anterior chamber . 342 
However, the choice of when or whether or not to do a paracentesis is ultimately at the 343 
investigator’s discretion. The full injection procedure is described in the protocol -specific study [ADDRESS_1039254] -injection  364 
requirements and risks if they do not follow  these requirement s. All partic ipants will be 365 
instructed to avoid high altitude travel until the surgeon confirms the gas bubble has cleared.  366 
Phakic p articipants in both groups will be asked to avoid the supi[INVESTIGATOR_759060] 367 
or the stomach during sleepi[INVESTIGATOR_491185] . 368 
All participants will be instructed to wear a wristband to notify healthcare providers that they 369 
should not receive nitrous oxide anesthesia until the gas bubble has cleared. For observation 370 
group participa nts, this will be the 4 -week visit.  371 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         4-1  
   CHAPTER 4:  FOLLOW -UP VISITS AND TESTING  372 
4.1 Study Visit s 373 
The schedule of protocol -specified follow -up visits is as follows:  374 
• 1 week ( - 4 days to + 3  days)  375 
• 4 (±1) weeks  376 
• 12 (± 2) weeks  377 
• 24 (±4) weeks  378 
4.1.1 Procedures at Study Visits  379 
The following procedures will be performed in both groups at all visits, unless otherwise 380 
specified : 381 
1. E-ETDRS visual acuity testing (best corrected) in each eye.  382 
• A protocol refraction in the study eye is required at  each visit . Refraction in the non-study [ADDRESS_1039255] 384 
recently performed refraction is used for the testing.  385 
• VA technicians will be masked to treatment group at all visits . 386 
2. Visual function testing ( myVisionTrack ) at [ADDRESS_1039256] using Zeiss Cirrus or Heidelberg Spectralis on the study eye  388 
• The same machine type (Cirrus or Spectralis) used at baseline must be used during 389 
follow -up 390 
• OCT technicians will be masked to treatmen t group at all visits.  391 
4. Ocular exam  in the study eye only , including slit lamp examination with lens assessment, 392 
measurement of IOP, and dilated ophthalmoscopy  393 
• The eye exam should be extensive enough to identify adverse events of interest  394 
• An extended ophthalmoscopy including a  scleral depression is required at 1, 4, and 12 395 
weeks to identify any retinal tears or detachments  396 
All of the testing procedures do not need to be performed on the same day, provided that they are 397 
completed within the tim e window of a visit . If data from a testing procedure is unusable ( e.g., if [ADDRESS_1039257] is ungradable), the participant may be asked to repeat the procedure during an additional [ADDRESS_1039258] DRCR Retin a 404 
Network  protocol for each procedure . 405 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         4-2  
   4.2 Treatment During Follow -Up 406 
4.2.1 Criteria for Vitrectomy  407 
Vitrectomy may be performed if one of the following  occurs : [ADDRESS_1039259] 10 letters at a single visit (not including the 1 -week visit) or [ADDRESS_1039260] 5 letters at two consecutive visits (not including t he 1-week visit) compared with 410 
baseline that is thought to be related to VMT  411 
2. Complication requires prompt surgical intervention (e.g. , macular hole , retinal de tachment, 412 
non-clearing vitreous hemorrhage ) [ADDRESS_1039261] be obtained for alternative treatment.  414 
4.2.2 Treatment for Other Conditions in the Study Eye  415 
An eye should not be enrolled that is anticipated to require intraocular treatment for another 416 
condition during the study. If a condition develops during follow -up requiring prompt treatment, 417 
it is at investigator discretion .  418 
4.2.3 Treatment in the Non -Study Eye  419 
Treatment in the non -study eye is at investigator discretion , except that gas injec tion for VMT is 420 
not permitted in the non -study eye during the study .  421 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         5-1  
   CHAPTER 5:  STUDY DEVICE  422 
5.1 Description of the Investigational Device  423 
Perfluoropropane (C3F8) is an inert gas under pressure and is administered by [CONTACT_491198] 424 
vitreous cavity.  It was approved by [CONTACT_81775] 1993 (P900066) for the use of placing [ADDRESS_1039262] 50 psi  and the cylinder is not expi[INVESTIGATOR_5697] .  430 
5.3 Safety Measures  431 
Preparation of the p erfluoropropane C 3F8 injection will be performed  in accordance with 432 
manufacturer labelling.  The full injection procedure is described in the protocol -specific study 433 
procedures manual. 434 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         6-1  
   CHAPTER 6:  ADVERSE EVENTS, DEVIC E ISSUES, AND STOPPI[INVESTIGATOR_16442]  435 
6.1 Adverse Events  436 
6.1.1 Definitions  437 
Adverse Event (AE):  Any untoward medical occurrence in a study participant, irrespective of the 438 
relationship between the adverse event and the device(s) under investigation (see section 6. 2 for 439 
reportable adverse events for this protocol) . 440 
Serious Adverse Event (SAE):  Any untoward medical occurrence that:  441 
• Results in death.  442 
• Is life -threatening; (a non -life-threatening event which, had it been more severe, might [ADDRESS_1039263] become life -threatening, is not nec essarily considered a serious adverse event).  444 
• Requires inpatient hospi[INVESTIGATOR_1081].  445 
• Results in persistent or significant disability/incapacity or substantial disruption of the [ADDRESS_1039264] normal life functio ns (e.g. sight threatening).  447 
• Is a congenital anomaly or birth defect.  448 
• Is considered a significant medical event by [CONTACT_13656] 449 
(e.g., may jeopardize the participant or may require medical/surgical intervention to 450 
prevent one of the outcomes listed above).  451 
In general, an ocular adverse event should be reported as serious (considered sight threatening) if 452 
it meets one of the following criteria:  453 
1. It causes a decrease of ≥ [ADDRESS_1039265] visua l acuity 454 
measurement prior to onset (e.g. central retinal artery occlusion) . 455 
2. In the opi[INVESTIGATOR_871], it requires prompt surgical intervention (e.g. 456 
vitrectomy, vitreous tap, intravitreous antibiotics , laser or cryosurgical retinopexy ) to [ADDRESS_1039266] (UADE):  Any serious adverse effect on health or safety or [ADDRESS_1039267], 463 
problem, or death was not previously identified in nature, severity , or degree of incidence in the 464 
investigational plan or application (including a supplementary plan or application), or any other 465 
unanticipated serious problem associated with a device that relates to the rights, safety, or 466 
welfare of participants (21 CFR 812.3(s)).  [ADDRESS_1039268] (ADE):  Any untoward medical occurrence in a study participant which [ADDRESS_1039269] contributed (Note that an Adverse 469 
Event Form is to be completed in addition to being reported on a Gas Injection Form ). 470 
Device Complaints:  A device complication or complaint is something that happens to a device or 471 
related to device performance, whereas an adverse event happens to a participant . A device 472 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         6-2  
   complaint may occur independently f rom an AE, or along with an AE . An AE may occur without 473 
a device complaint or there may be an AE related to a device complaint.  474 
Device Malfunction:  Any failure of a device to meet its performance specifications or otherwise 475 
perform as intended . Performance  specifications include all claims made in the labeling for the 476 
device . The intended performance of a device refers to the intended use for which the device is 477 
labeled or marketed. (21 CFR 803.3)  [ADDRESS_1039270] medical occurrence that 480 
meets one of the following criteria:  481 
1) an ocular AE in the study eye , 482 
2) a serious AE, 483 
3) an Adverse Device Effect (ADE) as defined in section 6.1.1 , or 484 
4) an AE occurring in association with a study procedure .  [ADDRESS_1039271] been caused 492 
by [CONTACT_19911].  493 
To ensure consistency of adverse event causality assessments, investigators should apply the 494 
following general guideline when dete rmining whether an adverse event is related:  495 
Yes 496 
There is a plausible temporal relationship between the onset of the adverse event and the study 497 
intervention, and the adverse event cannot be readily explained by [CONTACT_2299]’s clinical state, 498 
intercurre nt illness, or concomitant therapi[INVESTIGATOR_014]; and/or the adverse event follows a known pattern 499 
of response to the study intervention . 500 
No 501 
Evidence exists that the adverse event has an etiology other than the study intervention (e.g., pre - 502 
existing medical condition, underlying disease, intercurrent illness, or concomitant medication) , 503 
and/or the adverse event has no plausible temporal relationship to study intervention.  504 
6.1.4 Intensity of Adverse Event  505 
The intensity of an adverse event will be rated on a 3 point scale: (1) mild, (2) moderate, or (3) 506 
severe . It is emphasized that the term severe is a measure of intensity: thus a severe adverse 507 
event is not necessarily serious . For example, itching for several days may be rated as severe, but 508 
may not be clinically s erious.  509 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         6-3  
   • MILD: Usually transient, requires no special treatment, and does not interfere with the 510 
participant’s daily activities.  511 
• MODERATE: Usually causes a low level of inconvenience or concern to the participant 512 
and may interfere with daily activities, but  is usually ameliorated by [CONTACT_91118] 513 
measures.  514 
• SEVERE: Interrupts a participant’s usual daily activities and generally requires systemic 515 
drug therapy or other treatment.  516 
6.1.5 Coding of Adverse Events  517 
Adverse events will be coded using the MedDRA dictionary . The Medical Monitor will review 518 
the investigator’s assessment of causality and may agree or disagree . Both the investigator’s and 519 
Medical Monitor’s assessments will be recorded . The Medical Monitor will have the final say in 520 
determining the cau sality.  521 
Adverse events that continue after the participant’s discontinuation or completion of the study 522 
will be followed until their medical outcome is determined or until no further change in the 523 
condition is expected.  524 
6.1.6 Outcome of Adverse Event  525 
The outcome  of each reportable adverse event will be classified by [CONTACT_3470]:  526 
• COMPLETE RECOVERY/ RESOLVED : The participant recovered from the AE/SAE [ADDRESS_1039272] the AE/SAE stop date.  528 
• RECOVERED/ RESOLVED WITH SEQUELAE : The event persisted and had stabilized [ADDRESS_1039273] the AE/SAE stop date.  530 
• FATAL : A fatal outcome is defined as the SAE that resulted in death . Only the event that 531 
was the cause of death should be reported as fatal . Adverse events and serious  adverse 532 
events  that were ongoing at the time of death , that were not the cause of death, will be 533 
recorded as ‘resolved ’ at the time of death.  534 
• ONGOING : An ongoing AE/SAE is defined as the event was ongoing with an 535 
undetermined outcome.  536 
 An ongoing outcome for which further improvement or worsening is possible will 537 
require follow -up by [CONTACT_212412]/SAE.  538 
 An ongoing outcome that is medically stable (further change not expected) will be 539 
documented as such and will no t require additional follow -up.  540 
 The outcome of an ongoing event at the time of death that was not the cause of death, 541 
will be updated and recorded as ‘resolved ’ with the date of death recorded as the stop 542 
date.  543 
All adverse events occurring during the stud y and continuing at study termination should be 544 
followed by [CONTACT_2299]’s physician and evaluated with additional tests (if necessary) until [ADDRESS_1039274] be report ed to the 561 
Coordinating Center within 24 hours via completion of the online case report  form.  562 
The Coordinating Center will notify all participating investigators of any adverse event that is 563 
serious, related, and unexpected. Notification will be made within  10 days after the Coordinating 564 
Center becomes aware of the event.  565 
Each principal investigator [INVESTIGATOR_3411] -related adverse events and 566 
abiding by [CONTACT_66716]/her Institutional Review Board or 567 
Ethics Committee.  568 
Upon receipt of a UADE report, the JCHR  will investigate the UADE and if indicated, report the 569 
results of the investigation to the sites’ IRBs, and the FDA within 10 working days of the JCHR  570 
becoming aware of the UADE per 21CFR 812.46( b) (2) . The Medical Monitor must determine if [ADDRESS_1039275] receipt notice of the UADE.  575 
Device malfunctions will be handled by [CONTACT_491199] .  576 
6.5 Stoppi[INVESTIGATOR_2121]  577 
6.5.1 Criteria for Suspending or Stoppi[INVESTIGATOR_3396]  578 
The Data and Safety Monitoring Committee ( DSMC ) will be informed of all unanticipated [ADDRESS_1039276] su spension of study activities or stoppage of the 581 
study if deemed necessary based on the totality of safety data available.  582 
The study may be discontinued by [CONTACT_19305] (with approval of the DSMC ) prior [ADDRESS_1039277] of specific adverse events to be reported 589 
expeditiously to the DSMC will be compi[INVESTIGATOR_759061]  590 
document .  591 
6.7 Risks  592 
The potential risks associated with use of the study device are described in section 1.4.1.  593 
Additional risks are minor and/or infrequent and include:   594 
Risks Related to Testing Procedures  595 
Many  of the testing procedures in this study are part of daily ophthalmologic practice in the United 596 
States and pose few if any known risks.  597 
• Dilating eye drops will be used as part of the exam . There is a small risk of inducing a narrow - 598 
angle glaucoma attack from the pupil dilation . However, all participants will hav e had prior 599 
pupil dilation usually on multiple occasions and therefore the risk is extremely small .  600 
Risks Related Specifically to the Pre -Injection Preparation  601 
• There are potential side effects to subconjunctival anesthetic, which are rare . They include, but 602 
are not limited to, the following: damage to the eyeball by [CONTACT_98847], damage to the optic 603 
nerve, double vision lasting 24 hours or more.  604 
• Complications associated with paracentesis are uncommon, but may include uveitis, flat 605 
anterior chamber, corneal wound leak, hyphema, anterior vitreous prolapse, and/or pupi[INVESTIGATOR_1396] [ADDRESS_1039278] . Under certain circumstances, such complications may lead to 607 
vision loss.  608 
Risks if Pregnant  609 
According to the C 3F8 package insert, there are no known teratogenic effects when injected into 610 
the eye; however, caution should be used in pregnant women . Therefore, patients will not be [ADDRESS_1039279].  614 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         7-1  
   CHAPTER 7:  MISCELLANEOUS CONSIDERATIONS  [ADDRESS_1039280]  be worn until the investigator confirms that the gas bubble has cleared (at 4 - 620 
week visit for observation group  participants).  [ADDRESS_1039281] to follow -up. 629 
For participants w ho withdraw, their data will be used up until the time of withdrawal.  630 
7.3 Discontinuation of Study  631 
The study may be discontinued by [CONTACT_19305] (with approval of the DSMC ) prior [ADDRESS_1039282] 642 
month after enrollment . Additional phone contacts from the Coordinating Center will be made if 643 
necessary to facilitate the scheduling of the study participant for follow -up visits . A participant - 644 
oriented newsletter and a study logo item may be sent once .  645 
Study participants will be provided with a summary of the study results in a newsletter format 646 
after completion of the study by [CONTACT_55473] .  647 
7.5 Participant Compensation  648 
Participant  compensation will be specified in the informed consent form.  649 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         8-1  
   CHAPTER 8:  STATISTICAL CONSIDERATIONS  [ADDRESS_1039283] of superiority will be used in evaluating the following hypotheses for the primary 657 
outcome:  658 
Null Hypothesis (H 0): There is no difference in the proportion of  eyes with  central VMT release 659 
without rescue treatment between the PVL and observation groups at 24 weeks.  660 
Alternative Hypothesis (H a): There is a difference in the proportion of eyes with  central VMT 661 
release  without rescue treatment  between the PVL and observation  groups at 24 weeks.  662 
Similar hypothesis tests will be conducted for all secondary, exploratory, and safety outcomes.  663 
8.3 Sample Size  664 
8.3.1 Outcome Projections:  665 
Observation Group (sham injection)  666 
In a consecutive case series of 106 eyes with a median follow -up time of 18 months,6 the 667 
proportion of eyes with  spontaneous VMT release was 32%. The proportion of eyes w ith VMT 668 
release at 6 months in the Sham Groups of the randomized controlled trials MIVI -TRUST10 669 
(N = 188) and OASIS (N = 74),11 which compared ocriplasmin versus sham for VMT, were 670 
approximately 13% and 10%, respectively. Dugel et al.11 also found that the proportion of eyes 671 
with VMT release was greater among eyes that had MH at baseline. Macular hole was present at 672 
baseline in approximately 36% of the OASIS Sham Group and 25% of the MIVI -TRUST Sham 673 
Group.  674 
PVL group  675 
Three case series provide  estimates of VMT release with C 3F8 gas. A study of 15 eyes (1 with 676 
MH) from Rodrigues et al.23 showed release of VMT in 60% of ey es through 6 months. Steinle 677 
et al.24 showed 83% success among 30 eyes (3 with MH) through  62 days. Finally, Chan et al.25 678 
(2017) showed 86% success among 50 eyes (15 with MH) over 9 weeks. In addition, Chan et al. 679 
reported higher rates of VMT release among eyes with MH. The release rate among eyes with 680 
VMT only in Chan et al. was 80%.25 681 
8.3.2 Sample Size Estimates  682 
Table 1 shows sample size estimates for the primary analysis under varying assumptions for the 683 
proportion of eyes with VMT release within the 2 groups. These ca lculations assume a Type I 684 
error rate of 5%, 90% power, and a two -sided test of superiority (See Section 8.6) with a null 685 
hypothesis of no difference between the groups (Section 8.2).  686 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         8-2  
   Table 1: Comparison of Proportion with VMT Release: Total Sample Size  687 
Release in PVL 
Group  Release in Sham Group  
10%  20%  30%  
50%  52 104 248 
60%  34 60 112 
70%  24 38 62 
For true outcome proportion of 60% (PVL) vs 30% (sham injection), a sample size of 112 (56 688 
per group) gives 90% power to reject the null hypothesis of no difference. Adjusting for possible 689 
loss to follow -up of 10% gives a final sample size of 124 (62 per group).  690 
8.4 Outcome Measures  691 
For the outcomes below, rescue treatment includes vitrectomy, ocriplasmin, or additional 692 
pneumatic vitreolysis du ring the course of the study.  693 
Primary Efficacy Outcome:  694 
• Proportion of eyes with central VMT release * without rescue treatment at 24 weeks.  695 
o For purposes of description only, the distribution of eyes within treatment group 696 
by [CONTACT_759069] 24 weeks will be tabulated without statistical 697 
comparison:  698 
▪ Central VMT release without rescue treatment  699 
▪ Central VMT release with rescue treatment  700 
▪ No central VMT release and no rescue treatment  701 
▪ No central VMT release despi[INVESTIGATOR_491187]  702 
Secondary Efficacy Outcomes:  703 
• Proportion of eyes with central VMT release* without rescue treatment through 24 weeks 704 
(time -to-event analysis).  705 
• Proportion of eyes with central VMT release and vitreopapi[INVESTIGATOR_491188]* without 706 
rescue treatment at 24 we eks. 707 
• Mean change  in visual acuity letter score from baseline at 24 weeks.  708 
• Proportion of eyes with at least 10 -letter gain (increase) in visual acuity from baseline at 709 
24 weeks.  710 
• Proportion of eyes with at least 10 -letter loss (decrease) in visual acuity fro m baseline at 711 
24 weeks.  712 
• Proportion of eyes receiving rescue treatment before the 24 -week visit . 713 
o For purposes of description only, the following will be tabulated within treatment 714 
group without statistical comparison:  715 
▪ Proportion of eyes receiving rescue treatment before the 24 -week visit or 716 
for which rescue treatment is planned at the 24 -week visit and medical 717 
records confirm rescue treatment occurred within the subsequent 12 718 
weeks.  719 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         8-3  
   ▪ Type of rescue treatment.  720 
Exploratory Efficacy Outcomes:  721 
• Mean change in shape discrimination hyperacuity from baseline at 24 weeks.  722 
• Proportion of eyes with ellipsoid zone* integrity at 24 weeks.  723 
*Determined by [CONTACT_491200].  [ADDRESS_1039284] on  analyses of continuous outcomes, 725 
change in continuous outcomes from baseline will be truncated to ± [ADDRESS_1039285] deviation from both treatment groups combined at 24 weeks.  727 
8.5 Analysis Cohorts  728 
• Intention -To-Treat  (ITT) Analysis Cohort: all randomized participants irrespective of 729 
treatment received, and analyzed according to treatment assignment.  730 
• Safety Analysis Cohort: all randomized participants irrespective of treatment received, 731 
and analyzed according to treatm ent assignment.  732 
• Per-Protocol Analysis Cohort: only participants that complete the initial treatment (PVL 733 
or sham injection) and do not receive any non -protocol treatments during follow -up. [ADDRESS_1039286]. The per -protocol analysis will only be performed if  more than 741 
10% of randomized participants would be excluded by [CONTACT_91980] (e.g., 13 or more 742 
participants if exactly 124 are enrolled).  [ADDRESS_1039287] the hypothesis of superiority (Secti on 8.2). Presence of ERM [ADDRESS_1039288] indicated the rate of VMT release differs by [CONTACT_759070] 753 
randomization schedules were therefore stratified by  [CONTACT_759071]. The relative risk 754 
(estimated using the method of Localio  et al.  200727) for the treatment group effect, 95% [ADDRESS_1039289] prior release or rescue treatment documented. The imputation model will include presence 764 
of ERM within 1 mm of the center of the macula at baseline,  treatment group, and VMT status at 765 
1, 4, 12, and 24 weeks.  766 
A sensitivity analysis will be conducted using the same approach as above but without multiple 767 
imputation (i.e., complete -case analysis).  [ADDRESS_1039290] ratio along with the 95% confidence interval and P value will be [ADDRESS_1039291] release or that receive rescue treatment will be 776 
censored on the date of their final visit.  777 
The proportion of eyes with central VMT release and vitreopapi[INVESTIGATOR_491188] (without 778 
rescue treatment) at [ADDRESS_1039292] variance estimation. Presence of ERM 784 
within 1 mm of the center of the macula at baseline and baseline visual acuity will be included as 785 
covariates. The treatment group difference, 95% confidence interval, and P value will be [ADDRESS_1039293] squares means and associated 95% confidence intervals [ADDRESS_1039294] 10 -letter gain (increase) or loss (decrease) in visual acuity 794 
from baseline are binary variables that will be analyzed with logistic regression and will use the 795 
imputed data sets from the analysis of mean change in visu al acuity from baseline.  796 
The proportion of eyes receiving rescue treatment before the 24 -week visit is a binary variable 797 
that will be analyzed with logistic regression. The presence of ERM within 1 mm of the center of 798 
the macula at baseline will be include d as a covariate.  Complete -case analysis (no imputation of 799 
missing data) will be used for this outcome.  800 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         8-5  
   8.7.2 Exploratory Efficacy Outcomes  801 
Change in shape discrimination hyperacuity  (measured in logMAR) is a continuous variable that 802 
will be analyzed as ab ove but substituting baseline and follow -up shape discrimination 803 
hyperacuity  for visual acuity. Complete -case analysis (no imputation of missing data) will be 804 
used for this outcome.  805 
The proportion of eyes with ellipsoid integrity  at 24 weeks is a binary va riable graded by [CONTACT_941] 806 
central reading center (loss of integrity and no loss of integrity). Logistic regression adjusted for [ADDRESS_1039295], 95% confidence interval, and P value will used to compare treatment groups. To 810 
aid in interpretation of the relative risk, observed outcome proportions will be reported for each 811 
treatment  group. Complete -case analysis (no imputation of missing data) will be used for this 812 
outcome.  813 
8.8 Safety Analyses  814 
All reportable adverse events will be categorized as study eye or systemic. All events will be 815 
tabulated by [CONTACT_121610] a listing of each r eported Medical Dictionary for Regulatory 816 
Activities (MedDRA) term and summarized over each MedDRA System Organ Class. All [ADDRESS_1039296]’s unconditional exact test. The following ocular adverse events are of primary [ADDRESS_1039297]:  [ADDRESS_1039298] extraction in eyes phakic at baseline  828 
o Vitreous hemorrhage  829 
o Adverse IOP events (composite outcome)  830 
▪ Increase in IOP ≥ 10 mmHg from baseline (at a follow -up visit)  831 
▪ IOP ≥ 30 mmHg (at a follow -up visit)  832 
▪ Initiation of medication to lower IOP that was not in use at baseline  833 
▪ Glaucoma procedure  [ADDRESS_1039299]’s unconditional exac t test. The following systemic adverse events are of primary [ADDRESS_1039300]:  841 
o Death  842 
o Serious adverse event (at least one)  [ADDRESS_1039301] and will be tabulated without 844 
statistical comparison:  [ADDRESS_1039302] one 846 
serious event  847 
For each treatment group, the number of adverse events (ocular or systemic) considered related 848 
to treatment will be tabulated.  849 
8.9 Intervention Adherence  850 
Adherence will be defined as completion of the treatment assigned at randomization, either PVL 851 
or sham injection.  852 
8.10 Protocol Adherence and Retention  853 
Protocol deviations and visit completion rates (excluding deaths) will be tabulated for each 854 
treatment group.  855 
8.11 Baseline Descriptive Stat istics  856 
Baseline characteristics will be tabulated by [CONTACT_759072] 857 
to the distribution will be reported.  858 
8.12 Planned Interim Analyses  859 
There is no formal interim analysis planned for this study. The Data and Safety Monitory 860 
Committee (DSMC) will review safety and outcome data approximately every [ADDRESS_1039303] modification (interaction), will be conducted for 864 
the primary outcome. These anal yses will be considered exploratory. Additionally, interpretation 865 
of the analyses will depend on whether the primary analysis demonstrates a significant treatment 866 
group difference; in the absence of such a difference, subgroup analyses will be interpreted with 867 
caution.  868 
The general approach for these exploratory analyses will be to add an interaction term for the 869 
subgroup factor by [CONTACT_759073]. In addition, within -subgroup 870 
treatment effects and 95% confidence intervals will be estimated from the interaction model if [ADDRESS_1039304] VMT release  or rescue treatment prior to 24 weeks (i.e., complete case 873 
analysis as described  in section 8.6).  [ADDRESS_1039305] on the release rate in the observation group.  878 
Secondary subgroup analyses will include ERM presence at the site of vitreous adhesion, lens 879 
status (phakic or pseudophakic), components of VMT severity grade,[ADDRESS_1039306] (less than or equal to 1500 microns or greater than 1500 microns), and diabetes status (has [ADDRESS_1039307] diabetes).  [ADDRESS_1039308] will vary by [CONTACT_38881]/ethnicity. However, 883 
both of these factors will be evaluated in exploratory subgroup analyses as mandated by [CONTACT_432336] 884 
Institutes of Health (NIH) guidelines.  [ADDRESS_1039309] 20 eyes in each subgroup for each treatment group.  888 
8.14 Multiple Testing  889 
There will be no formal adjustment for multiple testing. Only P ≤ .[ADDRESS_1039310].  891 
8.15 Assessment of Confounding  892 
Imbalances between groups in important covariates are not expected to be of sufficient 893 
magnitude to produce confounding. How ever, a sensitivity analysis using observed data (no 894 
multiple imputation) will be conducted if there is an imbalance between treatment groups in any 895 
of the following: presence of ERM, lens status, extent of VMT, diabetes status, age, or sex. [ADDRESS_1039311] on the 898 
primary outcome.  The sensitivity analysis will mimic the primary analysis b ut add any 899 
potentially imbalanced factors as covariates. 900 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         9-1  
   CHAPTER 9:  DATA COLLECTION  AND MONITORING  901 
9.1 Case Report Forms and Device Data  902 
The main study data are collected through electronic case report forms (CRFs) . These electronic [ADDRESS_1039312] visit was completed (expected to be December 31, 2026) . These documents should 910 
be retained for a longer period, however, if required by [CONTACT_427] . No records will be 911 
destroyed without the written consent of JCHR .  912 
9.3 Quality Assurance and Monitoring  913 
Designated personnel from the Coordinating Center will be responsible for maintaining quality 914 
assurance (QA) and quality control (QC) systems to ensure that the clinical portion of the trial is 915 
conducted and data are generated, documented and reported in compliance with the protocol, 916 
Good Clinical Practice (GCP) and the applicable regulatory requirements . Adverse eve nts will be 917 
prioritized for monitoring.  918 
A risk -based monitoring (RBM) plan will be developed and revised as needed during the course 919 
of the study, consistent with the FDA “Guidance for Industry Oversight of Clinical 920 
Investigations — A Risk -Based Approach t o Monitoring” (August 2013) . Study conduct and 921 
monitoring will conform with 21 Code of Federal Regulations (CFR) 812.  [ADDRESS_1039313] important  data for monitoring at the site are participant eligibility and adverse events . 923 
Therefore, the RBM plan will focus on t hese areas . As much as possible, remote monitoring will 924 
be performed in real -time with on -site monitoring performed to evaluate the verity and 925 
completeness of the key site data . Elements of the RBM may include:  926 
• Qualification assessment, training, and certi fication for sites and site personnel  927 
• Oversight of Institutional Review Board (IRB) coverage and informed consent 928 
procedures  929 
• Central (remote) data monitoring: validation of data entry, data edits/audit trail, protocol 930 
review of entered data and edits, stat istical monitoring, study closeout  931 
• On-site monitoring (site visits): source data verification, site visit report  932 
• Communications with site staff  933 
• Patient retention and visit completion  934 
• Quality control reports  935 
• Management of noncompliance  936 
• Documenting monitorin g activities  937 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         9-2  
   • Adverse event reporting and monitoring  [ADDRESS_1039314] and progress of 941 
the study.  942 
9.4 Protocol Deviations  943 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or procedure 944 
requirements . The noncompliance may be either on the part of the participant, the investigator, or 945 
the study site staff . As a result of deviations, corrective actions are to be developed by [CONTACT_779] 946 
and implemented promptly.  947 
The site principal investigator  [INVESTIGATOR_759062] 948 
IRB requirements . Further details about the handling of protocol deviations will be included in 949 
the monitoring plan.  950 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         10-1  
   CHAPTER 10:  ETHICS/PROTECTION OF HUMAN PARTICIPANTS  [ADDRESS_1039315]  952 
The principal  investigator [INVESTIGATOR_759063] 953 
Regulations for the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 954 
CFR Part 50, 21 CFR Part 56, and/or the ICH E6.  955 
10.2 Institutional Review Boards  956 
The p rotocol, informed consent form(s), recruitment materials, and all participant materials will [ADDRESS_1039316] be obtained before any participant is enrolled . Any amendment to the protocol will 959 
require review and approval by [CONTACT_3484] . All 960 
changes to the consent form will be IRB approved; a determination will be made regarding 961 
whether previously consented participants ne ed to be re -consented.  962 
10.3 Informed Consent Process  963 
10.3.1  Consent Procedures and Documentation  964 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in 965 
the study and continues throughout the individual’s study participatio n. Extensive discussion of [ADDRESS_1039317] all documents and records required to be maintained by [CONTACT_093], including 989 
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         10-2  
   but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the 990 
participants in this study . The clinical study site will permit access to such records.  991 
The study participant’s contact [CONTACT_595080] 992 
internal use during the study . At the end of the study, all records will continue to be kept in a 993 
secure location for as long a period as dictated by [CONTACT_759074].  994 
Study participant research data, which is fo r purposes of statistical analysis and scientific 995 
reporting, will be transmitted to and stored at the coordinating center, the Jaeb Center for Health 996 
Research (JCHR) in Tampa, FL . This will not include the participant’s contact [CONTACT_491202] [ADDRESS_1039318] protected . At the end of 1000  
the study, all study databases will be de -identified and archived at JCHR . 1001  
10.3.3  Future Use of Stored Specimens  1002  
With the participant’s approval, de -identified biological samples will be stored at a central [ADDRESS_1039319] to biosample storage will not be possible after the study is completed.  1010  
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         11-1  
   CHAPTER 11:  REFERENCES  1011  
 1012  
1. Jackson TL, Nicod E, Simpson A, Angelis A, Grimaccia F, Kanavos P. Symptomatic 1013  
vitreomacular adhesion. Retina.  2013;33(8):1503 -11. 1014  
2. Duker JS, Kaiser PK, Binder S, et al. The International Vitreomacular Traction Study 1015  
Group classification of vitreomacular  adhesion, traction, and macular hole. 1016  
Ophthalmology.  2013;120(12):[ADDRESS_1039320], Chin EK. Spontaneous resolution of vitreomacular traction in two patients 1018  
with diabetic macular edema. Case Rep Ophthalmol.  2014;5(1):66 -71. 1019  
4. Dimopoulos S, Bartz -Schmidt KU, Gelisken F, Januschowski K, Ziemssen F. Rate and 1020  
timing of spontaneous resolution in a vitreomacular traction group: should the role of 1021  
watchful waiting be re -evaluated as an alternative to ocriplasmin therapy? Br J 1022  
Ophthalmol.  2015;99(3):350 -3. 1023  
5. Hwang DJ, Park KH, Woo SJ. Spontaneous resolution of vitreomacular traction 1024  
syndrome with persistent vitreofoveal adhesion observed on spectral -domain optical 1025  
coherence tomography. Can J Ophthalmol.  2012;47(5):e17 -9. 1026  
6. John VJ, Flynn HW, Jr., Smiddy WE , et al. Clinical course of vitreomacular adhesion 1027  
managed by [CONTACT_491204]. Retina.  2014;34(3):442 -6. 1028  
7. Theodossiadis GP, Grigoropoulos VG, Theodoropoulou S, Datseris I, Theodossiadis PG. 1029  
Spontaneous resolution of vitreomacular traction demonstrate d by [CONTACT_211682] -domain 1030  
optical coherence tomography. Am J Ophthalmol.  2014;157(4):842 -51 e1.  1031  
8. Tzu JH, John VJ, Flynn HW, Jr., et al. Clinical Course of Vitreomacular Traction 1032  
Managed Initially by [CONTACT_759075]. Ophthalmic Surg Lasers Imaging Retina.  1033  
2015;46( 5):[ADDRESS_1039321] Rev.  2017;10:CD011874.  1036  
10. Stalmans P, Benz MS, Gandorfer A, et al. Enzymatic vitreolysis with ocriplasmin for 1037  
vitreomac ular traction and macular holes. N Engl J Med.  2012;367(7):606 -15. 1038  
11. Dugel PU, Tolentino M, Feiner L, Kozma P, Leroy A. Results of the 2 -Year Ocriplasmin 1039  
for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole 1040  
(OASIS) Randomized Trial. Ophthalmology.  2016;123(10):2232 -47. 1041  
12. Stefanini FR, Maia M, Falabe lla P, et al. Profile of ocriplasmin and its potential in the 1042  
treatment of vitreomacular adhesion. Clin Ophthalmol.  2014;8:847 -56. 1043  
13. Lim J, Glassman A, Aiello L, et al. Macula Society collaborative retrospective study of 1044  
ocriplasmin for symptomatic vitre omacular adhesion. Ophthal Retina.  2017;1(5):413 -20. 1045  
14. Fahim AT, Khan NW, Johnson MW. Acute panretinal structural and functional 1046  
abnormalities after intravitreous ocriplasmin injection. JAMA Ophthalmol.  1047  
2014;132(4):484 -6. 1048  
15. Freund KB, Shah SA, Shah VP.  Correlation of transient vision loss with outer retinal 1049  
disruption following intravitreal ocriplasmin. Eye (Lond).  2013;27(6):[ADDRESS_1039322] the RPE - 1051  
photoreceptor adhesion in macular  holes? Br J Ophthalmol.  2015;99(5):635 -8. 1052  
17. Kim JE. Safety and complications of ocriplasmin: ocriplasmin, ocriplasmin; oh, how safe 1053  
art thou? JAMA Ophthalmol.  2014;132(4):379 -80. 1054  
Jaeb Center for Health Research  
 
Gas for VMT v3.0 7 -24-19         11-2  
   18. Tibbetts MD, Reichel E, Witkin AJ. Vision loss after intravitreal ocri plasmin: correlation 1055  
of spectral -domain optical coherence tomography and electroretinography. JAMA 1056  
Ophthalmol.  2014;132(4):487 -90. 1057  
19. American Society of Retina Specialists Preference and Trends (PAT) Survey 2017, 1058  
accessed at  www.asrs.org/asrs -commu nity/pat -survey . 1059  
20. Chan CK, Wessels IF, Friedrichsen EJ. Treatment of idiopathic macular holes by [CONTACT_491203] 1060  
posterior vitreous detachment. Ophthalmology.  1995;102(5):757 -67. 1061  
21. Costa RA, Cardillo JA,  Morales PH, Jorge R, Uno F, Farah ME. Optical coherence 1062  
tomography evaluation of idiopathic macular hole treatment by [CONTACT_134276] -assisted posterior 1063  
vitreous detachment. Am J Ophthalmol.  2001;132(2):264 -6. 1064  
22. Jorge R, Costa RA, Cardillo JA, Uno F, Bonomo PP, Far ah ME. Optical coherence 1065  
tomography evaluation of idiopathic macular hole treatment by [CONTACT_134276] -assisted posterior 1066  
vitreous detachment. Am J Ophthalmol.  2006;142(5):869 -71. 1067  
23. Rodrigues IA, Stangos AN, McHugh DA, Jackson TL. Intravitreal injection of expansile  1068  
perfluoropropane (c(3)f(8)) for the treatment of vitreomacular traction. Am J Ophthalmol.  1069  
2013;155(2):270 -6 e2.  1070  
24. Steinle NC, Dhoot DS, Quezada Ruiz C, et al. Treatment of Vitreomacular Traction with 1071  
Intravitreal Perfluoropropane (C3f8) Injection. Retin a. 2017;37(4):643 -50. 1072  
25. Chan CK, Crosson JN, Mein CE, Daher N. Pneumatic Vitreolysis for Relief of 1073  
Vitreomacular Traction. Retina.  2017.  1074  
26. Chan C. Pneumatic Vitreolysis for Resolving Focal Vitreomacular Traction: An Update 1075  
on Clinical Outcome . 2019 Re tina Society, 52nd Scientific Program, Landmark Hotel, 1076  
London, [LOCATION_006], Sept 11 to 15, 2019.  1077  
27. Localio AR, Margolis DJ, Berlin JA. Relative risks and confidence intervals were easily 1078  
computed indirectly from multivariable logistic regression. J Clin Epi[INVESTIGATOR_5541] . 1079  
2007;60(9):874 -82. 1080  
 1081  